Following last week's passage of the fiscal year (FY) 2026 spending package - which funds most federal agencies and programs through September 2026 - Congress can now turn its attention to policy issues beyond appropriations.

Last week, Reps. Jack Bergman (R-Mich.) and Jake Auchincloss (D-Mass.) introduced H.R. 7391, legislation that would ensure that federally-qualified health centers (FQHC) are not required to pay more than the 340B ceiling price for covered outpatient drugs. The association opposes this bill. While it acknowledges valid concerns with the previously proposed rebate model, the legislation ultimately takes a narrow approach. By protecting only FQHCs, the legislation fails to account for the serious and unique harm a rebate model would cause essential hospitals.

On the administrative side, the Department of Health and Human Services said that it would scrap the current 340B Rebate Model Pilot Program and potentially restart the process for such a program, according to a court filing last week

The association continues to engage lawmakers to underscore how the 340B program is working as intended for essential hospitals and the communities they serve.

Committee Activity This Week

The House and Senate are in session Monday through Thursday this week, with the Senate also convening on Friday.

The House Committee on Energy and Commerce will hold a health subcommittee hearing on Wednesday, Feb. 11, at 10:15 am ET, titled, "Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain". The association will submit a statement for the congressional record in support of the 340B Drug Pricing Program.

The Senate Committee on Health, Education, Labor, and Pensions will hold a full committee hearing, titled, "Restoring Integrity: Preventing Fraud in Child Care Assistance Programs", on Thursday, Feb. 12, at 10 am ET.

Join the Federal Action Network Today!

Stay connected to the latest from Washington. Join our Federal Action Network (FAN) - free for members - and gain exclusive access to advocacy expertise and updates.